1.• Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479–96. doi:10.1177/0269881113482532. Perspective piece on the history and current use of amphetamine.

2. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des. 2009;15(14):1563–86.

3. Papakostas GI, Nelson JC, Kasper S, Moller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2008;18(2):122–7. doi:10.1016/j.euroneuro.2007.07.005.

4. Papakostas GI, Worthington 3rd JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006;23(3):178–81. doi:10.1002/da.20181.

5. Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003;64(1):35–9.

6. Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, Fava M, Renshaw PF. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry. 2008;63(12):1127–34. doi:10.1016/j.biopsych.2007.11.020.

7. Mischoulon D, Best-Popescu C, Laposata M, Merens W, Murakami JL, Wu SL, et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008;18(9):639–45. doi:10.1016/j.euroneuro.2008.04.011.

8. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17. doi:10.1176/appi.ajp.163.11.1905.

9. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575–86. doi:10.1016/S0140-6736(13)61611-6.

10.• Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 2014;65(8):977–87. doi:10.1176/appi.ps.201300059. Review highlights the immense burden of treatment-resistant depression.

11. Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653–6. doi:10.1097/01.jcp.0000246212.03530.fd.

12. Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008;69(1):87–94.

13. Nolen WA, Haffmans PM, Bouvy PF, Duivenvoorden HJ. Hypnotics as concurrent medication in depression. A placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant. J Affect Disord. 1993;28(3):179–88.

14. Smith WT, Londborg PD, Glaudin V, Painter JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry. 1998;155(10):1339–45.

15. Dunlop BW, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Prim Care Companion J Clin Psychiatry. 2008;10(3):222–8.

16. Kho KH, Blansjaar BA, Vothknecht S, Cornelissen NM, Koomen E, Zwinderman AH, et al. A study into predictors for the speed of response to electroconvulsive therapy. J ECT. 2004;20(3):154–9.

17. Husain MM, Rush AJ, Fink M, Knapp R, Petrides G, Rummans T, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry. 2004;65(4):485–91.

18.• Abdallah CG, Averill LA, Krystal JH. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci. 2015;1344:66–77. doi:10.1111/nyas.12718. Review of primary literature of ketamine as prototype for the future of rapidly-acting antidepressant treatments.

19.• Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6(3):97–114. doi:10.1177/2040622315579059. Review of primary literature of ketamine and other NMDA receptor antagonists for the treatment of depression.

20. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.

21. Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64.

22. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802. doi:10.1001/archgenpsychiatry.2010.90.

23. Zarate Jr CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–46. doi:10.1016/j.biopsych.2011.12.010.

24.• Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–42. doi:10.1176/appi.ajp.2013.13030392. Active-comparator (midazolam) controlled two-site double-blind, randomized trial supporting subanesthestic ketamine as a rapid treatment for depression.

25. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605–11. doi:10.4088/JCP.09m05327blu.

26.• Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31(4):335–43. doi:10.1002/da.22253. Analysis demonstrating ketamine’s implicit and explicit antisuicidal properties.

27. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522–6. doi:10.1016/j.biopsych.2009.04.029.

28.• Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75(9):e932-8. doi:10.4088/JCP.14m09049. Post-hoc analysis of ketamine’s superior antidepressant effects in patients with anxious depression.

29.• Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED et al. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. 2015;18(1). doi:10.1093/ijnp/pyu039.

30. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–45. Post-hoc analysis of ketamine’s superior antidepressant effects in patients with a family history of alcoholism.

31.• Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28(6):536–44. doi:10.1177/0269881114527361. Small, open label naturalistic study demonstrates that up to six low dose ketamine infusions can safely be given to patients on antidepressants.

32.• Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–6. doi:10.1016/j.biopsych.2012.06.022. Repeated-dose ketamine was associated with a rapid antidepressant effect in medication free patients with treatment-resistant depression.

33.• Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27(5):444–50. doi:10.1177/0269881113478283. Repeat doses of ketamine infusions at 0.5mg/kg over 100 min (a lower rate than previously reported) demonstrated similar efficacy and excellent tolerability.

34. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71–82. doi:10.1017/S1461145709000169.

35. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37(6):1526–33. doi:10.1038/npp.2011.338.

36. Zarate Jr CA, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153–5. doi:10.1176/appi.ajp.163.1.153.

37.• Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2013. doi:10.1038/mp.2013.130. [Lanicemine:], a low-trapping NMDA channel blocker, demonstrated sustained antidepressant efficacy with minimal psychotomimetic adverse effects, offering a potential advantage over ketamine.

38.• Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 2014;159:56–61. doi:10.1016/j.jad.2014.02.017. Dissociative side effects, as measured by the CADSS, mediated ketamine’s antidepressant effects in medication-free patients with treatment-resistant depression.

39.• Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21(2):140–9. doi:10.1097/01.pra.0000462606.17725.93. Data supporting GLYX-13, a functional glycine site partial agonist, for the treatment of resistant depression.

40.• Zorumski CF, Nagele P, Mennerick S, Conway CR. Treatment-resistant major depression: rationale for NMDA receptors as targets and nitrous oxide as therapy. Front Psychiatry. 2015;6:172. doi:10.3389/fpsyt.2015.00172. Data supporting the use of Nitrous Oxide for depression.

41.• Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M, et al. Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial. Biol Psychiatry. 2014. doi:10.1016/j.biopsych.2014.11.016. First primary data paper on nitrous oxide’s superior antidepressant effects compared to placebo.

42.• Yang C, Hashimoto K. Combination of nitrous oxide with isoflurane or scopolamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci. 2015;13(1):118–20. doi:10.9758/cpn.2015.13.1.118. Authors suggest that combining scopolamine or isoflurane with nitrous oxide therapy may be advantageous in the treatment of depression.

43.• Fuxe K, Borroto-Escuela DO. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opin Investig Drugs. 2015;24(9):1247–60. doi:10.1517/13543784.2015.1074175. Review of theoretical evidence of basimglurant for treating depression.

44.• Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Fontoura P, et al. P.2.f.027 The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2014;24(Supp. 2):S468. doi:10.1016/S0924-977X(14)70748-5.

45.• Umbricht D, Niggli M, Sanwald-Ducray P, Deptula D, Moore R, Grünbauer W, et al. P.2.f.021 Results of a double-blind placebo-controlled study of the antidepressant effects of the mGLU2 negative allosteric modulator RG1578. Eur Neuropsychopharmacol. 2015;25(Supp. 2):S447. doi:10.1016/S0924-977X(15)30600-3. Abstract showing that RG1578 lacks antidepressant efficacy over placebo.

46.• Je Jeon W, Dean B, Scarr E, Gibbons A. The role of muscarinic receptors in the pathophysiology of mood disorders: a potential novel treatment? Curr Neuropharmacol. 2015;13(6):739–49.

47. Janowsky DS, Overstreet DH. The role of acetylcholine mechanisms in mood disorders. New York, NY: Raven; 1995. Review on the potential use of manipulating the cholinergic system for treating mood disorders.

48. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121–9. doi:10.1001/archpsyc.63.10.1121.

49. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67(5):432–8. doi:10.1016/j.biopsych.2009.11.021.

50. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci. 2008;28(2):407–14. doi:10.1523/JNEUROSCI.4458-07.2008.

51. Filho CB, Del Fabbro L, de Gomes MG, Goes AT, Souza LC, Boeira SP, et al. Kappa-opioid receptors mediate the antidepressant-like activity of hesperidin in the mouse forced swimming test. Eur J Pharmacol. 2013;698(1-3):286–91. doi:10.1016/j.ejphar.2012.11.003.

52. Fava M, Memisoglu A, Thase ME, Bodkin JA, Trivedi MH, de Somer M, et al. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2016;appiajp201515070921. doi:10.1176/appi.ajp.2015.15070921.

53.• Rohan ML, Yamamoto RT, Ravichandran CT, Cayetano KR, Morales OG, Olson DP, et al. Rapid mood-elevating effects of low field magnetic stimulation in depression. Biol Psychiatry. 2014;76(3):186–93. doi:10.1016/j.biopsych.2013.10.024. Data demonstrating promise of LFMS for treating depression.